摘要
目的
研究粘着斑激酶(focal adhesion kinase,FAK)和基质金属蛋白酶-9(matrix metalloproteinase,MMP-9)在垂体腺瘤中的表达及意义。
方法
垂体腺瘤组织标本5O例,其中侵袭性27例,非侵袭性23例,利用免疫组化法检测并分析比较FAK及MMP-9在侵袭性垂体腺瘤和非侵袭性垂体腺瘤中的表达。
结果
侵袭性垂体腺瘤中FAK和MMP-9的表达均高于非侵袭性垂体腺瘤(P<0.05);在侵袭性垂体腺瘤中FAK和MMP-9的表达水平呈正相关(P<0.05)。
结论
垂体腺瘤的侵袭性与FAK、MMP-9的过度表达有关,FAK和MMP-9可作为辅助诊断侵袭性垂体腺瘤的一项生物学指标。
Objective
To explore the expressions of focal adhesion kinase(FAK) and matrix metalloproteinase(MMP-9) in the pituitary adenomas .
Methods
The expressions of FAK and MMP-9 were determined by immunohisto- chemical technique in 50 pituitary adenoma tissues samples obtained by surgery,including 27 invasive pituitary adenomas and 23 non-invasive pituitary adenomas.The relationships of FAK and MMP-9 expressions with tumor invasiveness and the relationship among FAK and MMP-9 expressions in invasive pituitary adenomas were analysed.
Results
The expressions of FAK and MMP-9 in the invasive pituitary adenomas are significantly higher than those in the non-invasive pituitary adenomas(P<0.05).The expression of FAK was positively related to that of MMP-9 in the invasive pituitary adenomas (P<0.05).
Conclusions
There was a significant correlation between invasive characters of pituitary adenomas and the over expression of FAK and MMP-9.It is suggested that the determination of expression levels of FAK and MMP-9 may be helpful to diagnosing invasive pituitary adenomas.
引文
[1] Cance WG, Harris JE , Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colontissues :Correlation with preinvasive and invesive phenotypes[J]. Clin cancer Res, 2000,6(6):2417-2423.
[2] MaungK, Easty DJ,Hill SP, et a.l Requirement for focal adhesion Kinase in tumor cell adhesion, Oncogene, 1999, 18 ( 48 ):6824-6828.
[3] Su JM, Gui L, Zhou YP, et al. Expression of focaladhesion kinase and alpha5 and beta1 integrins in carci-nomas and it s clinical significance[J]. World J Gastroenterol, 2002,8(4): 613 -616.
[4] Duxbury MS, Ito H, Zinner MJ, et al.Focal adhesionkinase gene silencing promotes anoikis and suppressesmetastasis of human pancreatic adenocarcinoma cells[J]. Surgery, 2004, 135(5): 555-557.
[5] Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteol ytically activates TGF-beta and promotes tumor invasion and angiogenesis [J].Genes Dev, 2000, 14(2):163-176.
[6]周晓平.侵袭性垂体腺瘤的诊断和治疗.临床神经外科杂志,2008,5:52-54.
[7] SchallerMD,Borgman CA,Cobb BS,et al. pp125FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Nati Acad Sc,i 1992, 89: 5192-5196.
[8] Webb DJ,DonaisK,Whitmore LA,et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Bio,l 2004,6: 154-161.
[9] TakinoT,NakadaM, MiyamoriH,etal. JSAP1/JIP3 cooperateswith focal adhesion kinase toregulatec-JunN-terminal kinase and cellmigratio[J]. BiolChem, 2005, 280(45): 37772- 37781.
[10] Thamilselvan V,Craig DH,Bsson MD.FAK association with multiple signal proteins mediates preasure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway [J].FASEB J,2007,21(8):1730.
[11] Bogoyevich MA.Signalling via stress-activated MAPK in the cardiovascular system [J].Biochim Biophys Acta,2007,1770(4):518
[12] Kahana O,Mickache M,Witz IP,et al.The focal adhesion kinase (P123FAK) is constitutively active in human malignant melanoma[J].Oncogene,2002,21:3969.
[13] Ryu SJ,Cho KA,Oh YS,et al.Role of Src-specific phosphorylation site on focal adhesion kinase for senescence-associated apoptosis resistance[J].Apoptosis,2006,11(3):303.
[14] Sonoda Y,Matsumoto Y,Funakoshi M,et al.Anti-aopptotic role of focal adhesion kinase(FAK).Induction of inhibitor of apoptosis proteins and apoptosis suppression by the over-expression of FAK in a human leukemic cell line,HL-60[J].J Biol Chem,2000, 275(21):16309.
[15] McLean GW,KomiyamaNH, Serrels B,et al. Specific deletion of focal adhesion kinase suppresses tumor formation and block smalignant progression [J]. Genes Dev, 2004, 18(24): 2998-3003.
[16] Webb DJ, DonaisK, Whitmore LA,et al. FAK-Src signalling through paxillin, ERK andMLCK regulates adhesion disassembly[J]. Nat Cell Bio,l 2004, 6(2): 154-161
[17] WuXiaoyang, Gan Boy,i YooYoungdong,etal. FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation[J].Dev Cel,l 2005, 9(2): 185-196.
[18] SternlichtMD, Werb Z. How matrix metalloproteinases regulate cell behavior [J]. Annu Rev CellDev Bio,l 2001, 17(1): 463~516.
[19] SomervilleRP, OblanderSA, Apte SS. Matrixmetalloproteinases:old dogswith new tricks [J]. Genome Bio,l 2003, 4(6): 216.
[20] Nelson AR, Fingleton B, RothenbergML,et al. Matrixmetallo-proteinases: biologic activity and clinical implications[J].J ClinOnco,l 2000, 18(5): 1135 ~1149.
[21] Xu X, Wang Y, Lauer-Fields JL,et al. Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin butnot shortpeptides [J].MatrixBio,l 2004, 23(3):171~181.
[22] Collier IE, Krasnov PA, Strongin AY,et al. Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen-binding domain from human 92-kDa type IV collagenase[J]. J BiolChem, 1992, 267(10): 6776~6781.
[23]鲁衍强,叶其壮.基质金属蛋白酶及其抑制剂[J].生命的化学,2002 ,22 (4) :348-350.
[24] Joo-Hyon Kim, Tae-Han Kim, Jin-Wook Jang,et al. Analysis ofmatrixmetallo- proteinasemRNAsmxpressed in hepatocellular carcinoma cell lines[J]. MolCells, 2001, 12 (1):32~4.
[25] HayasakaA, SuzukiN, Fujimoto, N,etal. Elevated plasma levels of matrixmetallo- proteinase-9 (92-kd type IV collagease/gelatinase B) in hepatocellular carcinoma[J]. Hepatology, 1996, 24(5): 1058~1062.
[26] Folkman J. Fundamental concepts of the angiogenic process[J].Curr-MolMed, 2003, 3 (7): 643~651.
[27]范伟,周峰,卢丽艳.大肠癌组织中p27kip l和MMP-9表达的意义[J].中华医药研究与创新, 2003, 2 (2): 19~21.
[28] SCHWARZBAUER J.Basement menbranes:Putting up the barriers[J].Curr Biol,1999,9 (7);R242~R244
[29] Hiratsuka S, NakamuraK, IwaiS,etal. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lungspecific metastasis [J]. CancerCel,l 2002, 2 (4): 289~300.
[30] Gomez DE, Alonso DF, Yoshiji H,et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological function. Eur J Cell Biol, 1997; 74∶111.
[31] Wilson C B.A decade of pituitary microsurgery : The herbert olivecrona lecture[J].JNenurosury ,1984,61(5):814-833.
[32] Zhang Y, Thant AA , Hiraiwa Y, et al. A role for focal adhesion kinase in hyluronan-dependent MMP-2 secretion in a human small cell lung carcinoma cell line[J]. Biochem Biophys Res Commun,2002,290(3):1123- 1126.
[33] SiesserPM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer[J].ClinCancerRes, 2006, 12(11pt1): 3233-3237.
[34] Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya VM.A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.[J]Cell Cycle. 2009 Aug;8(15):2435-43. Epub 2009 Aug 1.
[35] BjorklundM, Heikkila P, Koivunen E. Peptide inhibition of catalytic and non- catalytic activities ofmatrixmetalloproteinase-9 blocks tumor cell migration and invasion .[J]Biol Chem,2004, 279(28): 29589~29597.
[36] Arnesano F, Boccarelli A, Cornacchia D, Nushi F, Sasanelli R, Coluccia M, Natile G.Mechanistic Insight into the Inhibition of Matrix Metalloproteinases by Platinum Substrates (dagger).[J]Med Chem.2009 Sep 16.
[1] Perrin RM,Konopatskaya O,Qiu Y,et al.Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascuIar endothelial growth factor.Diabetologia 2005; 48(11):2422-2427.
[2] Konopatskaya O,Churchill AJ,Harper SJ,et a1.VEGFl65b,an endogenous C-terminal splice variant of VEGF,inhibits retinal neovascularization in mice.Mol vis 2006 May 26(12):626-32.
[3] Vidal S,Lloyd RV,Moya L,et a1.Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the ratpituitary[J].HistocheCytochem,2002,50(4):533-540.
[4] Goto F.Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels[J]. Lab Invest,1993,69(5):508-517.
[5] Senger,-D-R,Galli,-S-J,Dvorak,一A—M,et a1.Tumor cells secrete avascular permeability factor that promotes accumulation of ascites fluid[J].Science.1983 Feb 25;219(4587):983-5.
[6] Dvorak,一H-F,Brown,一L-F,Detmar,-M,et a1.Vascular perm eability factor/vascular endothelial growth factor, microvascular hyperpermeability , and angiogenesis [J].Am-J-Pathol.1995 May;146(5):1029-39.
[7] Brock TA,Dvorak HF,Senger DR.Tumor—secreted vascular permeability factor increases cytosolic Ca2+and von Willebran d factor release in human endothelia1.cells[J].Am J Patho1.1991;138(1):213
[8] Hurwitz H,Fehrenbacher L,Novotny W,et a1.Bevacizumab plusinnotecall,fluorouracil and leucovorin for metastatic colorcctalcancer.N Engl J Med 2004:350(23):2335—2342.
[9] Mamputu JC,Renier G Advanced glycation end-ducts increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression:inhibitory effect of antioxidants.JLeukoc Bjol 2004:75(6):1062一1069.
[10] Schwarzenbach H,Chakrabarti G,Paust HJ.et a1. Gonadotropin—mediated regulation of the murine VEGF expression in MA—10 Leydig ceIls.J Androl 2004;25(1):128.139.
[11] Beckman R A,Merrill MJ,Reinhold WC,et al.Expression of the vascular permeability factor/VEGF in central nervous system neoplasms.J Clin Invest.1993 Jan;91(1):153-9.
[12] Fukui S, Nawashiro H, Otani N, Ooigawa H, Yano A, Nomura N, Tokumaru AM, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Shima K.Vascular endothelial growth factor expression in pituitary adenomas.Acta Neurochir Suppl. 2003;86(1):519-21.
[13] Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L.Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas..EndocrPathol. 1999 Autumn;10(3):229-235.
[14] Borg SA, Kerry KE, Royds JA, Battersby RD, Jones TH. Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells.Eur J Endocrinol. 2005 Feb;152(2):293-300.
[15] Arita K, Kurisu K, Tominaga A, Sugiyama K, Eguchi K, Hama S, Yoshioka H, Yamasaki F, Kanou Y.Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma.Hiroshima J Med Sci. 2004 Jun; 53(2):23-7.
[16]孔燕国任祖渊苏长保王任直幸兵.外周血血管内皮生长因子在垂体腺瘤患者的表达.中国医学科学院学报.2004 Apr;26(2):164-7.
[17] Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGFA by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol, 2005, 169(4):681-91.
[18] Christinger HW, Fuh G, de Vos AM, et al. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem,2004,279(11): 10382-8.
[19] Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E,Stalla GK, Renner U.Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries:detection of a non-endothelial function of VEGF in pituitary tumours.J Endocrinol. 2006 Oct;191(1):249-61.
[20] Jain RK, Duda DG, Clark JW, et al.Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol,2006,3(1): 24-40.